We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

136 hedge funds and large institutions have $2.34B invested in MoonLake Immunotherapeutics in 2025 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 33 increasing their positions, 43 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

141% more call options, than puts

Call options by funds: $21.1M | Put options by funds: $8.78M

140% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 15

18% more funds holding

Funds holding: 115 → 136 (+21)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

5.92% less ownership

Funds ownership: 100.57% → 94.65% (-5.9%)

23% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 43

32% less capital invested

Capital invested by funds: $3.43B → $2.34B (-$1.09B)

Holders
136
Holders Change
+21
Holders Change %
+18.26%
% of All Funds
1.82%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
36
Increased
33
Reduced
43
Closed
15
Calls
$21.1M
Puts
$8.78M
Net Calls
+$12.3M
Net Calls Change
+$9.63M

Top Buyers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
+$15.1M
2
Millennium Management
Millennium Management
New York
+$14.8M
3
OCA
Octagon Capital Advisors
New York
+$12.8M
4
VPC
Vestal Point Capital
New York
+$8.62M
5
Franklin Resources
Franklin Resources
California
+$8.25M

Top Sellers

Rank Fund Capital Flow
1
Holocene Advisors
Holocene Advisors
New York
-$60.2M
2
PBA
Paradigm Biocapital Advisors
New York
-$49.3M
3
Citadel Advisors
Citadel Advisors
Florida
-$30.5M
4
Marshall Wace
Marshall Wace
United Kingdom
-$26M
5
EC
EcoR1 Capital
California
-$18M
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
51
Congress Asset Management
Massachusetts
$2.84M -$11.3K -263 -0.4%
Geode Capital Management
52
Geode Capital Management
Massachusetts
$2.3M +$1.9K +44 +0.1%
MAP
53
Moody Aldrich Partners
Massachusetts
$2.16M +$2.38M +55,245 New
Morgan Stanley
54
Morgan Stanley
New York
$2.12M +$310K +7,187 +15%
Dimensional Fund Advisors
55
Dimensional Fund Advisors
Texas
$2.09M -$469K -10,890 -17%
AA
56
ALPS Advisors
Colorado
$1.84M -$168K -3,894 -8%
NIP
57
Nicholas Investment Partners
California
$1.83M +$2.02M +46,933 New
RPAM
58
Rhenman & Partners Asset Management
Sweden
$1.76M +$1.94M +45,000 New
UBS AM
59
UBS AM
Illinois
$1.71M +$67.6K +1,568 +4%
HS
60
HighVista Strategies
Massachusetts
$1.7M – – –
Swiss National Bank
61
Swiss National Bank
Switzerland
$1.68M – – –
Two Sigma Investments
62
Two Sigma Investments
New York
$1.39M +$1.54M +35,638 New
ClearBridge Investments
63
ClearBridge Investments
New York
$1.27M -$464K -10,768 -25%
Wellington Management Group
64
Wellington Management Group
Massachusetts
$1.26M -$2.88M -66,935 -68%
SCM
65
Superstring Capital Management
New York
$1.26M +$1.39M +32,145 New
Tudor Investment Corp
66
Tudor Investment Corp
Connecticut
$1.23M +$1.36M +31,592 New
Jane Street
67
Jane Street
New York
$1.07M +$1.02M +23,771 +639%
SEI Investments
68
SEI Investments
Pennsylvania
$1.07M +$231K +5,363 +24%
Walleye Capital
69
Walleye Capital
New York
$1.05M -$7.85M -182,132 -87%
Two Sigma Advisers
70
Two Sigma Advisers
New York
$992K +$1.09M +25,400 New
CF
71
Cantor Fitzgerald
New York
$977K +$1.08M +25,000 New
CSS
72
Cubist Systematic Strategies
Connecticut
$970K +$1.07M +24,819 New
ZP
73
Zimmer Partners
New York
$957K +$1.06M +24,500 New
Verition Fund Management
74
Verition Fund Management
Connecticut
$950K +$1.05M +24,317 New
WC
75
Wexford Capital
Florida
$840K -$108K -2,500 -10%
1 2
3
4 5

MLTX Hedge Fund Activity: Q1 2025 in Review

136 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q1 2025, worth a combined $2.34B — down 32% from $3.43B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new MLTX positions and 15 closed out — a net gain of 21 holders — while 33 added to existing stakes and 43 trimmed.

The largest buyer was Logos Global Management, opening a new position worth an estimated $15.1M. The largest seller was Holocene Advisors, cutting an estimated $60.2M.

  • 136 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q1 2025, up from 115 in Q4 2024.
  • Funds reported $2.34B of MoonLake Immunotherapeutics stock for Q1 2025, down 32% quarter-over-quarter.
  • 36 funds opened new MoonLake Immunotherapeutics positions in Q1 2025 and 15 closed out, a net change of +21 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q1 2025 was Logos Global Management, an estimated $15.1M added.
  • The largest MoonLake Immunotherapeutics seller in Q1 2025 was Holocene Advisors, an estimated $60.2M sold.

Based on aggregated 13F filings for Q1 2025.